SAB Biotherapeutics SABS
-
-
-
已收盤：-
本益比明細
年季 | 收盤價 | 本業佔比% | 本益比(近四季) | 每股稅後盈餘(元) | 營業利益(千) | 稅後純益(百萬) |
|---|---|---|---|---|---|---|
| 2026Q1 | 3.83 | 106.34 | 14.7 | -0.35 | -19,998 | -19 |
| 2025Q4 | 3.74 | 93.89 | 9.5 | -0.46 | -15,770 | -17 |
| 2025Q3 | 2.01 | -27.87 | 1.32 | -12,679 | 45 | |
| 2025Q2 | 1.76 | 96.84 | -1.09 | -9,732 | -10 | |
| 2025Q1 | 1.36 | 210.1 | -0.56 | -10,772 | -5 | |
| 2024Q4 | 3.79 | 88.39 | -1.23 | -10,009 | -11 | |
| 2024Q3 | 2.7 | 110.11 | -1.11 | -11,309 | -10 | |
| 2024Q2 | 3.1 | 140.85 | -0.8 | -10,202 | -7 | |
| 2024Q1 | 4.54 | 230.12 | -0.54 | -11,391 | -5 | |
| 2023Q4 | 6.88 | 82.86 | -3.85 | -18,874 | -23 | |
| 2023Q3 | 6.3 | 105.76 | -0.97 | -5,323 | -5 | |
| 2023Q2 | 8.3 | 95.17 | -1.36 | -6,477 | -7 | |
| 2023Q1 | 4.4 | 101.94 | -1.46 | -7,402 | -7 | |
| 2022Q4 | 5.9 | 101.28 | -1.81 | -7,860 | -8 | |
| 2022Q3 | 7.01 | 111.45 | -1.6 | -7,807 | -7 | |
| 2022Q2 | 14.5 | 136.4 | -1.1 | -6,543 | -5 | |
| 2022Q1 | 37.6 | -582.71 | 0.2 | -6,707 | 1 | |
| 2021Q4 | 78.1 | 63.94 | -4.1 | -7,344 | -12 | |
| 2021Q3 | 101.51 | -1.6 | -336 | 0 | ||
| 2021Q2 | 100.17 | -1.1 | -2,873 | -3 |